An Italian cost-effectiveness analysis of paclitaxel albumin (nab®-paclitaxel) plus gemcitabine vs gemcibatine alone for metastatic pancreatic cancer patients: The APICE study

被引：0
|
作者：
Lazzaro, C. [1 ]
Barone, C. [2 ]
Caprioni, F. [3 ]
Cascinu, S. [4 ]
Falcone, A. [5 ]
Maiello, E. [6 ]
Milella, M. [7 ]
Pinto, C. [8 ]
Reni, M. [9 ]
Tortora, G. [10 ]
机构：
[1] Studio Econ Sanit, Pharmacoecon, Milan, Italy
[2] Policlin Univ A Gemelli, UOC Oncol Med, Med Interna, Rome, Italy
[3] IST Ist Nazl Ric Canc, IRCCS AOU San Martino, Oncol Med 1, Genoa, Italy
[4] Azienda Osped Univ Policlin Modena, Med Oncol, Modena, Italy
[5] Azienda Osped Univ S Chiara, Dept Oncol Presidio Ospedaliero, Pisa, Italy
[6] IRCCS Casa Sollievo Sofferenza, Dept Hematol Oncol, San Giovanni Rotondo, Italy
[7] Ist Regina Elena, SC Oncol Med A, Rome, Italy
[8] Azienda Osped Arcispedale Santa Maria Nuova IRCCS, SC Oncol, Reggio Emilia, Italy
[9] IRCCS San Raffaele, Med Oncol, Milan, Italy
[10] Azienda Osped Univ Integrata Verona Borgo Roma, Med Oncol, Verona, Italy
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw377.24
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1045P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] An Italian Cost-Effectiveness Analysis of Paclitaxel Albumin (nab®-paclitaxel) plus Gemcitabine vs Gemcibatine alone for Metastatic Pancreatic Cancer Patients: The APICE Study
    Lazzaro, C.
    Barone, C.
    Caprioni, F.
    Cascinu, S.
    Falcone, A.
    Maiello, E.
    Milella, M.
    Pinto, C.
    Reni, M.
    Tortora, G.
    ANNALS OF ONCOLOGY, 2016, 27
  • [2] An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) plus gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study
    Lazzaro, Carlo
    Barone, Carlo
    Caprioni, Francesco
    Cascinu, Stefano
    Falcone, Alfredo
    Maiello, Evaristo
    Milella, Michele
    Pinto, Carmine
    Reni, Michele
    Tortora, Giampaolo
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2018, 18 (04) : 435 - 446
  • [3] Matters arising: On the cost-effectiveness for the Italian National Health Service of nab-paclitaxel plus gemcitabine vs gemcitabine alone in metastatic pancreatic cancer
    Lazzaro, Carlo
    JOURNAL OF THE EGYPTIAN PUBLIC HEALTH ASSOCIATION, 2024, 99 (01):
  • [4] An Italian Cost-effectiveness Analysis of Paclitaxel Albumin (nab Paclitaxel) Vs Solvent-based Paclitaxel for Metastatic Breast Cancer Patients - the CONSTANZA Study
    Lazzaro, C.
    Bordonaro, R.
    Cognetti, F.
    Fabi, A.
    De Placido, S.
    Arpino, G.
    Marchetti, P.
    Botticelli, A.
    Pronzato, P.
    Martelli, E.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S93 - S93
  • [5] Cost-effectiveness of nab-paclitaxel plus gemcitabine versus erlotinib plus gemcitabine in metastatic pancreatic cancer
    Chiorean, E. Gabriela
    Whiting, Scott
    Binder, Gary
    Dranitsaris, George
    Manax, Victoria
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [6] An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study
    Lazzaro, Carlo
    Bordonaro, Roberto
    Cognetti, Francesco
    Fabi, Alessandra
    De Placido, Sabino
    Arpino, Grazia
    Marchetti, Paolo
    Botticelli, Andrea
    Pronzato, Paolo
    Martelli, Elisa
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2013, 5 : 125 - 135
  • [7] Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china
    Cui, Jiujie
    Zhang, Xiaochen
    Qu, Shuli
    Wang, Liwei
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (04) : 691 - 697
  • [8] Cost-Effectiveness of Nab-Paclitaxel and Gemcitabine Versus Gemcitabine Monotherapy for Patients with Unresectable Metastatic Pancreatic Cancer in Japan
    Morimoto, Kosuke
    Moriwaki, Kensuke
    Kaneyasu, Takako
    Nakayama, Hitomi
    Shimozuma, Kojiro
    VALUE IN HEALTH REGIONAL ISSUES, 2022, 28 : 54 - 60
  • [9] On cost-effectiveness analysis, quality-adjusted life years, and cost-effectiveness threshold values of gemcitabine plus nab-paclitaxel versus gemcitabine alone in metastatic pancreatic cancer in the French setting
    Lazzaro, Carlo
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [10] French multi-institutional cost-effectiveness analysis of gemcitabine plus nab-paclitaxel versus gemcitabine alone as second-line treatment in metastatic pancreatic cancer patients
    Demaziere, Amaury
    Mourgues, Charline
    Lambert, Celine
    Trevis, Sophie
    Bertucat, Helene
    Grange, Isabelle
    Pezet, Denis
    Sautou, Valerie
    Jary, Marine
    Gagniere, Johan
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
12345